Clinique Générale - Beaulieu

tel. +41 22 839 55 00

Clinique des Grangettes

tel. +41 22 305 03 33

Oncology investigations

SPECT/CT and scintigraphy with labelled octreotide (Octreoscan) or with MIBG

Preparation
MIBG: After advice from your doctor, you will have to stop taking certain heart medications (antihypertensives, anti-aryhmics) and certain medications against depression (anti-depressants) in the days preceding your examination. Iodine in the form of drops or tablets will be administered to you orally to protect your thyroid before the examination.

Scintigraphy with labelled octreotide (Octreoscan) : After advice from your doctor, you will have to stop taking somatostatine at least 24 hours before your examination. Please notify us if you have kidney failure or insulin-treated diabetes.

The process
The examination generally takes place over 3 days

Day 1
1st session
Includes the intravenous injection of the radiopharmaceutical (duration: 15 min).
2nd session
Includes the acquisition of the imaging (duration: 1 hr).
Between the two sessions (3 hr), you are free to leave the institute. You will be given a laxative medication.

Day 2 and day 3
The sessions include the acquisition of the imaging (duration: 1 hr per session)
During the examination under the camera please remain immobile.

Main clinical indications

  • Search for neuroendocrine tumour

Principle
Labelled octreotide imaging is based on the binding of a radiopharmaceutical analogue of a hormone (somatostatine), to certain somatostatine receptors expressed at the surface of the neuroendocrine and gastroenteropancreatic tumour cells. This binding is dependent on the abundance and on the type of somatostatine receptor. The tumour cells are visualised in the form of an increased activity on the scintigraphy.

The MIBG imaging is based on the uptake of a radiopharmaceutical analogue of a neurotransmitter by certain tumours of neuroendocrine origin secreting neurotransmitters (adrenaline, noradrenaline ...) as the pheochromocytoma and neuroblastoma. These tumours are visualised in the form of an increased activity on the scintigraphy.

Neuroendocrine tumour of the small intestine

Neuroendocrine tumour of the pancreas